Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate an investigational way to provide radiation therapy to treat early-stage breast cancer at the time of surgery.

Detailed Description
-----------------
This is a prospective single-arm phase II study designed to study the efficacy of high dose rate (HDR) brachytherapy with CT-imaging, single-fraction intraoperative radiation therapy (IORT). The study will accrue patients with early-stage breast cancer who will be treated with breast-conserving surgery (BCS). The main clinical eligibility criterion is based on suitability for accelerated partial breast irradiation. Patients may be eligible prior to receiving BCS or within 30 days of receiving BCS. Eligible patients that will undergo BCS will receive surgery according to the standard clinical practice in the Brachytherapy Suite in the Emily Couric Clinical Cancer Center. Patients that have already undergone BCS must meet all other eligibility criteria and are able to be treated with IORT within 30 days of their breast surgery. Eligible subjects will undergo a lumpectomy or re-excision lumpectomy according the standard clinical practice. Immediately following lumpectomy, the breast HDR brachytherapy applicator will be placed and CT imaging will be performed for treatment planning. After HDR brachytherapy is delivered, the applicator will be removed, and the breast surgeon will complete the skin closure. Although the ultimate goal of the study is to determine 5-year ipsilateral breast tumor recurrence (IBTR), all efforts will be made to follow the patients until death.

Official Title
-----------------
A Prospective Single-Arm Phase II Study To Investigate The Efficacy Of Single-Fraction Intraoperative Radiation Treatment Using A Multi-Lumen Balloon Applicator And In-Room CT Imaging For The Treatment Of Early-Stage Breast Cancer

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Device: IORT with CT-Guided HDR Brachytherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has elected breast conserving surgery or whole breast irradiation treatment for early-stage breast cancer. Tumor size must be less than or equal to 3 cm. Patient is 45 years of age or older. Exclusion Criteria: Male patients. Pregnant patients. Breast cancer that involves the skin or chest wall. History of ipsilateral breast cancer. Multicentric breast cancer in the ipsilateral breast. Known BRCA gene mutation. Patient with nodal disease. Patient is undergoing initial medical treatment (hormone or chemotherapy) to reduce tumor size. Patient with breast implants (does not include patients having implants AFTER intra-operative radiotherapy).

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IORT with CT-Guided HDR Brachytherapy<br>Patients will receive IORT with CT-guided HDR brachytherapy at the time of breast surgery. | Device: IORT with CT-Guided HDR Brachytherapy<br>* This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.<br>* Other names: Breast Lumpectomy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Local Breast Tumor Recurrence |  | Up to 60 Months After Treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Ipsilateral Breast Tumor (Not Local) Recurrence |  | Up to 60 Months After Treatment | 
| Rate of Distant Recurrence of Breast Cancer |  | Up to 60 Months After Treatment | 
| Cancer Specific-Survival and Overall Survival Response Rate |  | Minimum of 60 Months After Treatment | 
| Changes in Reported Patient and Physician Cosmetic Descriptions |  | Up to 60 Months After Treatment | 
| Comparison of Pre-and Post Pathology Stratum |  | Up to 60 Months After Treatment | 
| Changes in Patient-Reported Quality of Life |  | Up to 60 Months After Treatment | 
| Number of Participants with Adverse Events | Safety and toxicity of treatment will be determined with the Common Toxicity Criteria for Adverse Effects. | 24 Months After Treatment | 
| Changes of Radiographic Breast Appearance |  | Up to 60 Months After Treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer, early-stage, brachytherapy, IORT